Abstract

BackgroundThis systematic review aimed to present and critically appraise the available information on the efficacy of platelet rich plasma (PRP) in equine and human orthopedic therapeutics and to verify the influence of study design and methodology on the assumption of PRP’s efficacy. We searched Medline, PubMed, Embase, Bireme and Google Scholar without restrictions until July 2013. Randomized trials, human cohort clinical studies or case series with a control group on the use of PRP in tendons, ligaments or articular lesions were included. Equine clinical studies on the same topics were included independently of their design. Experimental studies relevant to the clarification of PRP’s effects and mechanisms of action in tissues of interest, conducted in any animal species, were selected.ResultsThis review included 123 studies. PRP’s beneficial effects were observed in 46.7% of the clinical studies, while the absence of positive effects was observed in 43.3%. Among experimental studies, 73% yielded positive results, and 7.9% yielded negative results. The most frequent flaws in the clinical trials’ designs were the lack of a true placebo group, poor product characterization, insufficient blinding, small sampling, short follow-up periods, and adoption of poor outcome measures. The methods employed for PRP preparation and administration and the selected outcome measures varied greatly. Poor study design was a common feature of equine clinical trials. From studies in which PRP had beneficial effects, 67.8% had an overall high risk of bias. From the studies in which PRP failed to exhibit beneficial effects, 67.8% had an overall low risk of bias.ConclusionsMost experimental studies revealed positive effects of PRP. Although the majority of equine clinical studies yielded positive results, the human clinical trials’ results failed to corroborate these findings. In both species, beneficial results were more frequently observed in studies with a high risk of bias. The use of PRP in musculoskeletal lesions, although safe and promising, has still not shown strong evidence in clinical scenarios.Electronic supplementary materialThe online version of this article (doi:10.1186/s12917-015-0403-z) contains supplementary material, which is available to authorized users.

Highlights

  • This systematic review aimed to present and critically appraise the available information on the efficacy of platelet rich plasma (PRP) in equine and human orthopedic therapeutics and to verify the influence of study design and methodology on the assumption of PRP’s efficacy

  • This systematic review was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement, an evidencebased, established guideline for systematic reviews published by the CONSORT group [13,14]

  • Studies that used PRP in conjunction with stem cells or other biomaterials, as regenerative/ anti-inflammatory therapies for other target tissues or in other medical fields were excluded. Because of their scarcity, were included independently of their design or level of evidence if they described the effects of PRP on tendon, ligament or articular injuries

Read more

Summary

Introduction

This systematic review aimed to present and critically appraise the available information on the efficacy of platelet rich plasma (PRP) in equine and human orthopedic therapeutics and to verify the influence of study design and methodology on the assumption of PRP’s efficacy. Randomized trials, human cohort clinical studies or case series with a control group on the use of PRP in tendons, ligaments or articular lesions were included. Among both, equine and human athletes, treating persistent or slow healing injuries poses a challenge for clinicians. These lesions, which frequently result in inadequate tissue reorganization and in a high re-injury rate, are often related to a long period of incapacity or to an unsatisfactory return to performance [1]. Several blood-derived products are available for intra-lesional injection, such as platelet-rich plasma (PRP) or plasma rich in growth factors, autologous conditioned serum, autologous blood preparations and autologous protein concentrate [1,2,3,4,5,6]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call